CD40配基化对乳腺癌细胞株和血管内皮细胞的作用  

Effect of CD40 ligandization on breast cancer cell line and endothelial vein cell lline in vitro

作　　者：蒋国勤[1] 吴斌[1] 刘燕[1] 

机构地区：[1]苏州大学附属第二医院普外科,江苏苏州215004

出　　处：《中国癌症杂志》2005年第5期435-437,441,共4页China Oncology

基　　金：苏州大学发展基金资助

摘　　要：目的:研究CD40配基化对乳腺癌细胞株和血管内皮细胞的作用。方法:间接免疫荧光法检测乳腺癌细胞株MDA-MB-231(简称M231)、EVC细胞、新鲜乳腺癌细胞表面的CD40、CD40L的表达。与CD40L、多柔比星等共培养72小时,MTT法检测细胞增殖。AnnexinV-PI标记以流式细胞仪分析细胞周期。结果:CD40高表达于乳腺癌细胞株M231、乳腺癌新鲜标本及血管内皮细胞,上述3种细胞基本不表达CD40L。CD40配基化能明显抑制乳腺癌细胞株使乳腺癌细胞处于凋亡和死亡;使血管内皮细胞处于早期凋亡而非死亡。与多柔比星相结合有协同作用。结论:CD40配基化对乳腺癌有双重治疗作用:抑制乳腺癌细胞的同时抑制肿瘤新生血管。Purpose：To investigate the effect of CD40 ligandization on breast cancer cell line and endothelial vein cell line.Methods：The expression of CD40 and its ligand on breast cancer cell line（M231）,EVC cell line,fresh clinic breast cancer cell were determined by indirect immunofluorescence assay with flow cytometry（FCM）analysis.Then M231 cells cultured with CD40 agonsitic monoclone antibody,adriamycin alone or is combinations for 72 hours and proliferation of M231 cells was determined by MTT assay.FCM was employed to study the cells＇ death or apopotosis with Annexin V-PI assay.Results：M231 and ECV cell line and fresh clinic breast cancer cell are highly expressed CD40 but no CD40L.CD40 ligandization can not only inhibit the proliferation of M231 cell line but also inhibit ECV cell line by promotin the death or apoptosis of these cells.Combined CD40 agonsitic monoclone antibody with adriamycin may obviously inhibit proliferation of M231 and ECV cell line.Conclusions：CD40 ligandization may have double therapeutie effect to breast cancer.inhibit the proliferation of breast cancer cell and inhibit tumor angiogenesis by inhibiting vascular endothelial cell.

关 键 词：乳腺癌 CD40 细胞凋亡 CD40配体 培养的肿瘤细胞 

分 类 号：R737.9[医药卫生—肿瘤]